Xenetic Biosciences Reports 2024 Financial Results

Xenetic Biosciences, Inc. reported its 2024 financial results, highlighting advancements in their DNase-based technology to tackle challenging cancer types. Favorable preclinical data indicate potential for DNase-based approaches targeting NETosis. Xenetic's strategic clinical focus involves partnerships with institutions for exploratory studies.

In 2024, collaborations with the University of Virginia and Scripps Research were extended. A new agreement with PeriNess Ltd. aims to manage studies combining DNase I with chemotherapy and immunotherapy for pancreatic carcinoma, colorectal cancer, and other solid tumors.

Financially, Xenetic saw a net loss of approximately $4 million for 2024. Research and development expenses fell by 5.9% to $3.3 million due to reduced spending on DNase development. The year concluded with $6.2 million in cash.